Oncogenic KRAS mutations, mainly G12D and G12V, are present in as high as 95% of pancreatic cancer patients and are critical for pancreatic cancer initiation and development; however, mutant KRAS alone is insufficient to drive PDAC in adults [7,8,9,10]. This evidence concerns the gene KRAS and pancreatic neoplasm.